Abstract Introduction Leicester Hospitals admit over 850 cases of fragility hip fracture annually. 25% of patients will suffer another fracture in the 5 years following their fragility hip fracture. Intravenous Zoledronate is recommended as a first line treatment option to reduce fracture risk. In 2023 our hospitals performance in the National hip fracture database (NHFD) showed we were significantly below the national average in secondary fracture prevention and patient follow-up at 120 days. (UHL data 2023 24.9% vs. national average 45.3%). This project sought to embed the use of intravenous zoledronate in our perioperative pathway and improve 120 day follow up. Method Introduced a new guideline for rapid loading of Vitamin D and administration of intravenous Zoledronate. Conducted teaching sessions and disseminated our guideline with all stakeholders. A standardised checklist was introduced and Royal Osteoporosis Society patient information leaflets given to all patients. Utilised our hospitals new text messaging system (accuryx) to design a post discharge questionnaire to explore patients’ experience of our service. Results Our data from the NHFD has shown a significant improvement from 24.9% of patients in 2023 receiving appropriate bone protection treatment to 69% in 2025. Utilising accuryx we have gained valuable feedback from patients with a response rate of 27%. Conclusion Changing practice required education of staff and the introduction of a new guideline into our established pathway. Patients treated with zoledronate should have a significant reduction in risk of further fractures. Feedback from patients has highlighted areas in need of improvement and that further work is needed to interact with patients who are unable to complete the 120 day text follow-up service.
Atkin et al. (Wed,) studied this question.